BCL-2/BCL-XL Inhibitor Combination for Drug-Resistant Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges with drug resistance and the need for synergistic combinations targeting multiple signaling pathways to enhance efficacy and reduce toxicity, particularly in hematological malignancies like AML and myelodysplastic syndrome.
Innovation Solution
A combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, such as homoharringtonine, is used to inhibit cancer cell proliferation and induce apoptosis synergistically, disrupting key protein complexes like Bcl-2:BIM, Mcl-1:BAK, and Bcl-1:PUMA, thereby overcoming drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single chemotherapeutic agent is used to treat cancer, then the treatment is simple and has fewer side effects, but drug resistance develops and treatment efficacy is insufficient
Solution Approach 1:
The patent combines a Bcl-2/Bcl-xL inhibitor with a chemotherapeutic agent into a fixed-dose combination product. This merging of two drugs with different mechanisms of action (apoptosis induction via Bcl-2 inhibition and direct cytotoxic effects of chemotherapy) creates a synergistic effect that overcomes drug resistance while maintaining simplified administration as a single combined therapy regimen
2Reliability
If multiple signaling pathways are targeted to enhance treatment efficacy, then synergistic therapeutic effect is achieved, but the combination complexity and potential toxicity increase
Solution Approach 1:
The patent optimizes the dosage parameters of the combined therapy by establishing specific dosage ranges for the Bcl-2/Bcl-xL inhibitor (0.1-10 mg/kg) and chemotherapeutic agent (1-100 mg/kg) that achieve synergistic anti-tumor effects while minimizing toxicity. This parameter optimization allows multiple pathways to be targeted effectively without proportionally increasing harmful effects
Data Source
AI summary
The present invention relates to a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.